Why it may matterVerify against the original reporting
Positive top-line momentum (35% Q2 growth; 51% six-month), margin improvements (57% Q2, 58% H1) and operating leverage amid capacity expansion provide a constructive view on profitability trajectory. Progress on partnerships and AI-enabled initiatives could unlock incremental revenue. However, near-term liquidity risk (cash $1.8M; equity deficit $3.8M) and ongoing losses cap upside until financing or cost controls improve cash burn.
AI summary
What happened, with direct paths to the underlying reporting
Vivos Therapeutics posted Q2 2026 revenue of $5.2 million, up 35% YoY, with six-month revenue of $10.3 million (up 51%). Gross margin rose to 57% in Q2 and 58% YTD as higher volumes improve mix, while operating expenses grew 12%. Management cites capacity expansion, an AI software conversion at SCN, and stronger referrals as catalysts, with potential multi-market cardiology partnerships wrapping up in Florida and Arizona, supporting a near-term revenue trajectory despite ongoing cash burn.
Revenue $5.2M in Q2'26; six months $10.3M, up 35%/51% YoY.
Gross margin 57% Q2; 58% H1; operating expenses up 12%.
Capacity expansion, SCN AI conversion, and referrals drive demand gains.
Cash $1.8M; stockholders’ equity deficit $3.8M; six-month net loss $13.27M.
Pending cardiology partnerships in Florida/Arizona; Q3 gains already visible.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
